Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB- 1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).